|
3.1.1 Tabac - e-cigs
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
Considering stakeholders in policy around secondary findings in genomics [Bill of Health]
|
|
|
|
|
|
One
proposition is to use dynamic forms of consent, which allow decisions
around the receipt of secondary findings (and other results) to be
changed over time. Using a digital interface, dynamic consent
facilitates ongoing communication and would allow participants to change
their consent choices at any time—accounting for decisions that are
often time- and context-dependent.
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
6.1 Observation
|
|
|
|
6.10 Politiques
|
|
|
The science–policy interface [Science]
|
|
|
|
|
|
How
do we ensure the effective role of science in public policy-making?
This well-worn, long-standing question reflects the fact that the answer
is not simple. Later this month in Brussels, scientists and
policy-makers will convene at the International Network for Government
Science Advice (INGSA) Forum to consider the most promising ways
forward.
|
|
|
|
|
|
|
6.10.1 Politiques (USA)
|
|
|
|
|
|
6.6 Publications
|
|
|
Are ‘predatory’ publishers’ days numbered? [STAT]
|
|
|
|
|
|
According
to the US Federal Trade Commission, at least one of these mimics,
called the OMICS Group, is a “predatory” publisher. And in a first-ever
move for the FTC, the agency is suing the company, saying that they are
bilking researchers out of potentially millions of dollars.
|
|
|
|
|
|
|
6.7.1 Bioinformatique
|
|
|
|
6.9 Controverses
|
|
|